My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer - Episode 5

The Role of PSA Doubling Time in Risk Assessment

,

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

  1. Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment?
    1. At what PSA doubling time thresholds do treatment recommendations change?
    2. How reliable is PSA doubling as a biomarker versus imaging or other tests?